Global InformationKadmon Corporation information
 | |
| Industry | Biotechnology |
|---|---|
| Founded | 2009 |
| Founder | Samuel D. Waksal |
| Headquarters | 450 East 29th Street, , New York, NY 10016 United States |
Number of locations | 4 |
Key people | Harlan W. Waksal, MD (CEO) Anastasios G. Konidaris (Interim Chairman) |
| Products | capecitabine, dofetilide, entecavir, ribavirin, temozolomide, tetrabenazine, tobramycin |
Number of employees | 101[1] |
| Parent | Sanofi |
| Website | kadmon.com |
Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal,[2][3] founder and former CEO of ImClone Systems, now fully merged into Eli Lilly and Company. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed.[4][5]
In September 2014, amid plans to take the company to an IPO Harlan W. Waksal, brother of Samuel Waksal, became President and Chief Executive Officer while Samuel Waksal remained on with the title Chief of Innovation, Science and Strategy.[6] In early 2016 Sam Waksal left Kadmon and in June the company filed paperwork for its IPO.[7][8] On July 27, 2016 the company's stock began trading on the NYSE under the symbol KDMN[9] but switched to NASDAQ in October 2020.[10] On 8 September 2021, Sanofi announced it would acquire the company for $1.9 billion.[11] The deal completed in November and its stock was deregistered as it became a subsidiary of Sanofi.
As of 2019 Kadmon had ongoing clinical trials for KD025 in specific fibrotic and neurodegenerative diseases and tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD.[12]
- ^ "Company Overview of Kadmon Holdings, LLC". Bloomberg L.P. Retrieved 8 March 2019.
- ^ "Biotechnology Company Overview of Kadmon Corporation, LLC". Bloomberg.com. Archived from the original on January 19, 2013. Retrieved 3 December 2012.
- ^ Bartiromo, Maria. "Sam Waksal, Kadmon Pharmaceuticals CEO". CNBC.com. Retrieved 4 December 2012.
- ^ "Former Imclone Chief Acquires Drug Company". The New York Times. 25 October 2010. Retrieved 7 December 2012.
- ^ "2012 Private financing $50MIL". FORM D. US Securities and Exchange Commission. Retrieved 7 December 2012.
- ^ "Kadmon Corporation Announces the Appointment of Dr. Harlan W. Waksal as President". Kadmon Corporation Announcements. Kadmon Corporation. Archived from the original on 13 November 2014. Retrieved 13 November 2014.
- ^ Lash, Alex (June 13, 2016). "Kadmon Seeks IPO With Unusual Terms That Benefit Waksal, Debt Holders". Xconomy. Retrieved September 25, 2016.
- ^ Carroll, John (June 10, 2016). "Sam Waksal Exited Kadmon With $25M Severance Deal Ahead of IPO". FierceBiotech. Retrieved September 25, 2016.
- ^ "Sam Waksal's Kadmon Holdings shares open below offering price in debut". CNBC LLC. Retrieved 25 September 2016.
- ^ Kadmon Corporation (October 13, 2020). "Kadmon to Transfer U.S. Stock Exchange Listing to Nasdaq" (Press release). Accesswire.
- ^ "France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 bln deal". Reuters.com. 2021-09-08. Retrieved 2021-09-08.
- ^ "35 Studies found for: Kadmon". Clinical Trials.gov. Retrieved March 8, 2019.